↓ Skip to main content

The early economic evaluation of novel biomarkers to accelerate their translation into clinical applications

Overview of attention for article published in Cost Effectiveness and Resource Allocation, June 2018
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Good Attention Score compared to outputs of the same age (72nd percentile)

Mentioned by

twitter
8 X users

Citations

dimensions_citation
9 Dimensions

Readers on

mendeley
57 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The early economic evaluation of novel biomarkers to accelerate their translation into clinical applications
Published in
Cost Effectiveness and Resource Allocation, June 2018
DOI 10.1186/s12962-018-0105-z
Pubmed ID
Authors

Gimon de Graaf, Douwe Postmus, Jan Westerink, Erik Buskens

Abstract

Translating prognostic and diagnostic biomarker candidates into clinical applications takes time, is very costly, and many candidates fail. It is therefore crucial to be able to select those biomarker candidates that have the highest chance of successfully being adopted in the clinic. This requires an early estimate of the potential clinical impact and commercial value. In this paper, we aim to demonstratively evaluate a set of novel biomarkers in terms of clinical impact and commercial value, using occurrence of cardiovascular disease (CVD) in type-2 diabetes (DM2) patients as a case study. We defined a clinical application for the novel biomarkers, and subsequently used data from a large cohort study in The Netherlands in a modeling exercise to assess the potential clinical impact and headroom for the biomarkers. The most likely application of the biomarkers would be to identify DM2 patients with a low CVD risk and subsequently withhold statin treatment. As a result, one additional CVD event in every 75 patients may be expected. The expected downstream savings resulted in a headroom for a point-of-care device ranging from €119.09 at a willingness to accept of €0 for one additional CVD event, to €0 at a willingness to accept of €15,614 or more. It is feasible to evaluate novel biomarkers on outcomes directly relevant to technological development and clinical adoption. Importantly, this may be attained at the same point in time and using the same data as used for the evaluation of association with disease and predictive power.

X Demographics

X Demographics

The data shown below were collected from the profiles of 8 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 57 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 57 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 16%
Researcher 8 14%
Student > Bachelor 7 12%
Student > Master 6 11%
Student > Doctoral Student 5 9%
Other 10 18%
Unknown 12 21%
Readers by discipline Count As %
Medicine and Dentistry 14 25%
Economics, Econometrics and Finance 6 11%
Business, Management and Accounting 3 5%
Nursing and Health Professions 3 5%
Biochemistry, Genetics and Molecular Biology 3 5%
Other 12 21%
Unknown 16 28%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 7. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 25 June 2018.
All research outputs
#4,626,639
of 22,716,996 outputs
Outputs from Cost Effectiveness and Resource Allocation
#161
of 421 outputs
Outputs of similar age
#89,826
of 327,012 outputs
Outputs of similar age from Cost Effectiveness and Resource Allocation
#12
of 12 outputs
Altmetric has tracked 22,716,996 research outputs across all sources so far. Compared to these this one has done well and is in the 79th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 421 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.2. This one has gotten more attention than average, scoring higher than 61% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 327,012 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 72% of its contemporaries.
We're also able to compare this research output to 12 others from the same source and published within six weeks on either side of this one. This one is in the 8th percentile – i.e., 8% of its contemporaries scored the same or lower than it.